

LIST OF CLAIMS

1. (Original) A microplasmin polypeptide comprising a heterologous loop domain sequence, wherein said polypeptide is resistant to $\alpha 2$ -antiplasmin inhibition compared to a wild type microplasmin.
2. (Original) The polypeptide of claim 1, wherein said heterologous loop domain comprises at least 4 consecutive amino acids of a factor D loop domain.
3. (Original) The polypeptide of claim 1, wherein said heterologous loop domain comprises at least 10 consecutive amino acids of a factor D loop domain.
4. (Original) The polypeptide of claim 1, wherein said polypeptide comprises a heterologous loop domain sequence in microplasmin loop 3.
5. (Original) The polypeptide of claim 1, wherein said polypeptide comprises amino acid sequence LNGA (SEQ ID NO:1) in microplasmin loop 3.
6. (Original) The polypeptide of claim 1, wherein said polypeptide comprises a heterologous loop domain sequence in microplasmin loop 5.
7. (Original) The polypeptide of claim 1, wherein said polypeptide comprises amino acid sequence AHCLEDAADGKV (SEQ ID NO:2) in microplasmin loop 5.
8. (Original) The polypeptide of claim 1, wherein said polypeptide comprises a heterologous loop domain sequence in microplasmin loop 6.
9. (Original) The polypeptide of claim 1, wherein said polypeptide comprises amino acid sequence AHSLSQPEPSK (SEQ ID NO:3) in microplasmin loop 6.

10. (Original) The polypeptide of claim 1, wherein said polypeptide comprises a heterologous loop domain sequence in microplasmin loop 7.
11. (Original) The polypeptide of claim 1, wherein said polypeptide comprises amino acid sequence HPDSQPDTIDHD (SEQ ID NO:4) in microplasmin loop 7.
12. (Withdrawn) A method of dissolving a blood clot, comprising contacting said blood clot with the polypeptide of claim 1.
13. (Withdrawn) A substantially pure fragment of plasminogen, wherein said fragment is activated at least 10% more efficiently compared to human glu-plasminogen.
14. (Withdrawn) The fragment of claim 13, wherein said fragment comprises at least 150 consecutive residues of SEQ ID NO:17.
15. (Withdrawn) The fragment of claim 13, wherein said fragment comprises a methionine residue at the N-terminal end.
16. (Withdrawn) A substantially pure polypeptide comprising residues 550-810 of SEQ ID NO:17, wherein residue 555 is not a cysteine residue.
17. (Withdrawn) A substantially pure polypeptide comprising residues 550-810 of SEQ ID NO:17, wherein residue 560 is not a cysteine residue.
18. (Withdrawn) A substantially pure polypeptide comprising residues 550-810 of SEQ ID NO:17, wherein residue 580 is not an arginine residue.
19. (Withdrawn) A substantially pure polypeptide comprising residues 481-810 of SEQ ID NO:17, wherein residue 555 is not a cysteine residue or wherein residue 560 is not a cysteine residue.

APPLICANTS: Guy L. Reed
SERIAL NUMBER: 10/715,981

20. (Withdrawn) A substantially pure polypeptide comprising residues 481-810 of SEQ ID NO:17, wherein residue 580 is not an arginine residue.